EMORY UNIVERSITY
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1836-12-10
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.emory.edu
Clinical Trials
1.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1134 trials with phase data)• Click on a phase to view related trials
Baricitinib Curative Repression of HIV-1
- Conditions
- HIV InfectionHIV
- Interventions
- Drug: Antiretroviral Therapy (ART)
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT07209267
- Locations
- 🇺🇸
Grady Infectious Diseases Clinic (Ponce Center), Atlanta, Georgia, United States
🇺🇸Dr. Gavegnano's Laboratory, Atlanta, Georgia, United States
Quantifying Multi-step Avoidance in Anxiety
- Conditions
- AnxietyAnxiety Disorders
- First Posted Date
- 2025-10-02
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Emory University
- Target Recruit Count
- 163
- Registration Number
- NCT07203027
- Locations
- 🇺🇸
Emory College, Atlanta, Georgia, United States
🇺🇸Facility for Education and Research in Neuroscience (FERN), Atlanta, Georgia, United States
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
- Conditions
- Neisseria Meningitidis
- Interventions
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Emory University
- Target Recruit Count
- 125
- Registration Number
- NCT07197762
- Locations
- 🇺🇸
Emory Children's Center-Vaccine Research Clinic, Atlanta, Georgia, United States
🇺🇸Hope Clinic, Atlanta, Georgia, United States
PKU Protein Requirements
- Conditions
- PKU
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT07194993
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
Effectiveness- Implementation Trial of the Function-Based Elopement Treatment
- Conditions
- Autism Spectrum Disorder
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT07194083
- Locations
- 🇺🇸
Marcus Autism Center, Atlanta, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 270
- Next
News
Virax Biolabs Partners with Emory University for Long COVID Diagnostic Study Using T Cell Technology
Virax Biolabs has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies of ViraxImmune™ technology for diagnosing long COVID and other post-viral syndromes.
Aligos Therapeutics Initiates Phase 2 Trial of ALG-000184 for Chronic Hepatitis B Treatment
Aligos Therapeutics has begun dosing patients in the Phase 2 B-SUPREME study of ALG-000184, an investigational oral therapy for chronic hepatitis B virus infection.
Psilocybin Shows Anti-Aging Properties in Preclinical Study, Extending Cellular Lifespan by 50%
Emory University researchers demonstrated that psilocin, the active metabolite of psilocybin, extended human skin and lung cell lifespans by more than 50% in laboratory studies.
CDC Sponsors First Clinical Trial of Needle-Free Rotavirus Vaccine Using Dissolvable Microarray Patch Technology
Emory University and Micron Biomedical have launched the first CDC-sponsored clinical trial of a rotavirus vaccine delivered via dissolvable microarray patch technology, marking a significant milestone in needle-free vaccine administration.
Ryght AI Secures $3M Seed Funding and Expands Academic Partnerships to Accelerate Clinical Trial Site Selection
Ryght AI raised $3 million in seed funding led by Foothill Ventures to advance its AI-powered clinical trial platform that creates digital twins of over 100,000 research sites worldwide.
FDA Approves Hundreds of Drugs Without Adequate Evidence of Effectiveness, Investigation Reveals
A two-year investigation found that 73% of the 429 drugs approved by the FDA from 2013-2022 failed to meet the agency's four foundational standards for proving effectiveness.
Long-Term Study Confirms Hydroxyurea's Safety and Efficacy in Pediatric Sickle Cell Disease
Children with sickle cell disease taking hydroxyurea experienced fewer emergency room visits and shorter hospital stays compared to those not on the therapy, according to a study of 2,147 pediatric patients.
Vaccinex's Pepinemab Shows Promise in Turning "Cold" Tumors "Hot" Through Enhanced Immune Response
Vaccinex will present new clinical data at ASCO 2025 showing that neoadjuvant treatment with pepinemab induces mature tertiary lymphoid structures that correlate with improved pathologic response in head and neck cancer patients.
Loneliness Epidemic Shifts: Middle-Aged Americans More Isolated Than Seniors, New Research Reveals
One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.
Expanded GLP-1 Drug Access Could Save 42,000 Lives and Billions in Healthcare Costs Annually
Expanding access to GLP-1 weight-loss medications like Ozempic and Zepbound could prevent more than 42,000 deaths annually in the United States, according to a recent Yale study published in PNAS.